The mechanism of action of a normophasic oral contraceptive 'Fysioquens'.
Six women with normal menstrual cycles were treated over six cycles with Fysioquens, a normophasic contraceptive consisting of 7 tablets of ethinyloestradiol (EE) 0-050 mg and 15 tablets containing 1-0 mg lynestrenol + 0-050 mg EE. In the 1st, 3rd and 6th treatment cycles and in the cycles before and after treatment, hormonal assays and other tests were carried out to determine whether ovulation had occurred. No treatment cycles showed any signs of ovulation, but it did occur in the pre-and post-treatment cycles. Blood pressures and liver function tests remained normal, but two of the six volunteers showed a slight increase in body-weight.
D000328:Adult; D001706:Biopsy; D002582:Cervix Mucus / Q000378:metabolism; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004717:Endometrium / Q000473:pathology; D004967:Estrogens / Q000097:blood; D004997:Ethinyl Estradiol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008234:Lynestrenol / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects; D011276:Pregnanediol / Q000097:blood; D011374:Progesterone / Q000097:blood; D014621:Vagina / Q000166:cytology
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D004997:Ethinyl Estradiol; D011374:Progesterone; D007986:Luteinizing Hormone; D011276:Pregnanediol; D008234:Lynestrenol